<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706069</url>
  </required_header>
  <id_info>
    <org_study_id>CT/07.06</org_study_id>
    <nct_id>NCT00706069</nct_id>
  </id_info>
  <brief_title>Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study Of Vinorelbine Oral Plus Capecitabine Combination In Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the toxicity and secondary the efficacy of the combination
      vinorelbine plus capecitabine in metastatic breast cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination capecitabine-vinorelbine, with iv administration of vinorelbine, has been
      studied in a phase [I]/[II], with favourable profile of toxicity in pretreated patients with
      anthracyclines and/or taxanes (Oncology News International vol 12, no 3, suppl 2, 2003).

      In a study of toxicity and effectiveness, Vanhopher reported objective response rates (PR) in
      21 from 45 patients (47%) and stabilization of disease (SD) in 16 patients (36%). Severe
      leucopenia (grade 4), was reported in 5% of patients (Borquez D, et al: Proc Am Soc Clin
      Oncol 19: Abstract 420, 2000)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of vinorelbine oral plus capecitabine combination</measure>
    <time_frame>Toxicity assessment at 1st cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity (DLT) of vinorelbine oral plus capecitabine combination.</measure>
    <time_frame>Toxicity assessment at 1st cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Response evaluation at 3rd and 6th cycle by CT's or MRI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine oral plus Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine oral</intervention_name>
    <description>Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Navelbine oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic breast cancer

          -  Age 18-75 years

          -  Bidimensionally measurable or evaluable disease

          -  Performance status (PS) 0-2 (ECOG)

          -  Patients with reproductive potential must use an adequate contraceptive method (e.g.,
             abstinence, intrauterine device, oral contraceptives, barrier device with spermicide,
             or surgical sterilization) during treatment and for three months after completing
             treatment

          -  Adequate liver (serum bilirubin &lt;1.5 times the upper normal limit, AST and ALT &lt;2.5
             times the UNL in the absence of demonstrable liver metastases, or &lt;5 times the upper
             normal limit in the presence of liver metastases); adequate renal function (serum
             creatinine &lt;1.5 times the upper normal limit); and adequate bone marrow
             function(neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)

          -  At least three weeks from completion of irradiation

          -  Life expectancy ≥ 12 weeks

          -  Patients able to take oral medication

          -  written informed consent

        Exclusion Criteria:

          -  Active infection

          -  Brain metastases

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  Malnutrition (loss of ≥ 20% of the original body weight)

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikos Malamos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Marika Iliadis&quot; Hospital of Athens, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dept. of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Marika Iliadis&quot; Hospital of Athens, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nikos Malamos</name_title>
    <organization>Hellenic Oncology Research Group</organization>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Vinorelbine oral</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

